Ascendis (ASND) to present TransCon CNP Week 104 trial data orally
Ascendis announces an oral presentation of Week 104 data from its pivotal TransCon CNP (navepegritide) trial at ISDS 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.